127 related articles for article (PubMed ID: 6140637)
1. Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Gerlach J; Casey DE
Mod Probl Pharmacopsychiatry; 1983; 21():97-110. PubMed ID: 6140637
[No Abstract] [Full Text] [Related]
2. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
3. Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
Friedhoff AJ; Rosengarten H; Bonnet K
Psychopharmacol Bull; 1978 Oct; 14(4):77-9. PubMed ID: 704769
[No Abstract] [Full Text] [Related]
4. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Kamenetskiĭ VK
Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
[No Abstract] [Full Text] [Related]
5. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Shoulson I
Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
[No Abstract] [Full Text] [Related]
6. Dopamine antagonist and agonist treatment of tardive dyskinesia.
Bjørndal N; Casey D; Gerlach J
Adv Biochem Psychopharmacol; 1980; 24():541-5. PubMed ID: 6105800
[No Abstract] [Full Text] [Related]
7. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Greenacre JK; Coxon A; Petrie A; Reid JL
Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
[TBL] [Abstract][Full Text] [Related]
8. Combined use of benserazide and carbidopa in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
[TBL] [Abstract][Full Text] [Related]
9. Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Goetz CG; Klawans HL; Carvey P
Mod Probl Pharmacopsychiatry; 1983; 21():5-20. PubMed ID: 6140633
[No Abstract] [Full Text] [Related]
10. Response to Sinemet 25/100 in Parkinson's disease.
Ulm G; Gerdes U; Lehmann K
Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
[No Abstract] [Full Text] [Related]
11. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
[TBL] [Abstract][Full Text] [Related]
13. Levodopa with benserazide or carbidopa in Parkinson disease.
Rinne UK; Mölsä P
Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
[TBL] [Abstract][Full Text] [Related]
14. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
15. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
Alpert M; Friedhoff AJ; Diamond F
Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444
[No Abstract] [Full Text] [Related]
16. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
[TBL] [Abstract][Full Text] [Related]
17. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
Rabadeau Dumas JL; Rondot P; Cardon P
Therapie; 1977; 32(2):161-72. PubMed ID: 898124
[No Abstract] [Full Text] [Related]
18. Madopar HBS and the decompensated phase of Parkinson disease.
Caraceni T; Nordera N; Lamperti E; Lorizio A
Ital J Neurol Sci; 1989 Aug; 10(4):407-14. PubMed ID: 2793413
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Mondal BK; Mondal KN
Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
[TBL] [Abstract][Full Text] [Related]
20. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
